Download or read book The European Pharmaceutical Industry and the Development of Biotechnology written by European Federation of Pharmaceutical Industries' Associations and published by . This book was released on 1984 with total page 36 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Research Development of the European Pharmaceutical Industry written by Arne Noack and published by GRIN Verlag. This book was released on 2007-11 with total page 54 pages. Available in PDF, EPUB and Kindle. Book excerpt: Seminar paper from the year 2003 in the subject Business economics - Operations Research, grade: A, Vrije University Brussel (Vesalius College), course: Economics, language: English, abstract: The health of their population has always been a great concern for governments of Post-War Europe. In order to achieve their goals they had to work closely together with the pharmaceutical Industry. With the phenomenon of the aging population the importance of development of new drugs is increasing. The increasingly old population of Europe creates a big market for pharmaceutical companies. The pharmaceutical Industry is a very complex sector with close links to other Industries. The chemical Industry for example is an important supplier for materials needed in the process of creating new drugs. Furthermore is the market for pharmaceuticals characterized by extremely little concentration and a huge variety of products. Globally in 1998, the 300 best-selling products held a share of less than 45% of the worlds market. The top two products held 1.3% of the market each.1 This fact creates a necessity for the companies to research new, so called "Blockbuster drugs" to succeed on this market with a high competition. The data on the various methods of drug discovery is enormous and sophisticated. In this paper the structure of the Research & Development sector of the European pharmaceutical industry will be examined, which is of increasing importance for the success of the individual companies. The specific data on the R & D section will be given a general character. Furthermore it will give a brief overview of the different regions in Europe and their individual differences. In the end, the difficulties and challenges of R & D in the pharmaceutical industry will be described and compared to other pharma markets abroad. [1 Data taken from "Combining discovery with development" by Dr. Peter Eddershaw; World pharmaceutical frontiers 2003/2004 ]
Download or read book The Business of Healthcare Innovation written by Lawton R. Burns and published by Cambridge University Press. This book was released on 2005-08-25 with total page 400 pages. Available in PDF, EPUB and Kindle. Book excerpt: The first wide-ranging analysis of business trends in the manufacturing segment of the health care industry.
Download or read book 1992 Planning for Chemicals Pharmaceuticals and Biotechnology written by Eurofi Plc and published by Elsevier. This book was released on 2013-10-22 with total page 412 pages. Available in PDF, EPUB and Kindle. Book excerpt: 1992-Planning for Chemicals, Pharmaceuticals and Biotechnology provides a summary of the relevant legislation, research programs, and proposals for the establishment of a single European market for the chemical, pharmaceutical, and biotechnology industries. The development of the European Community's (EC) policy and the implications of its implementation for the EC and third country markets are discussed. The views from a number of major organizations that operate in the chemical, pharmaceutical, and biotechnology markets are considered to provide an insight into some of the factors influencing strategic planning for 1992. This book consists of 10 chapters and opens with an overview of the EC's goal of establishing a single market for the European Union by 1992, followed by a discussion on the implications of this single market for industry, commerce, and individuals. The following chapters focus on the Single European Act; corporate issues such as mergers and acquisitions; standards of good practice in the chemical, pharmaceutical, and biotechnology sectors; and implications of a single European market for these industries. The final chapter is devoted to the views of organizations in the chemical, pharmaceutical, and biotechnology sectors such as the European Chemical Industry Federation (CEFIC), Bayer AG, and COLIPA (European Cosmetic Industry Federation) in terms of the opportunities, problems, and challenges of the single European market. This monograph will be a useful resource for corporate managers, especially those in the IT sector, as well as policymakers and industry regulators.
Download or read book Business Development for the Biotechnology and Pharmaceutical Industry written by Martin Austin and published by Gower Publishing, Ltd.. This book was released on 2008 with total page 216 pages. Available in PDF, EPUB and Kindle. Book excerpt: In recognition of the sparse information available to practitioners in the field of business development, Martin Austin has drawn on his 30 years of experience in the pharmaceutical industry to provide this highly practical guide spanning the complete process. Based on the well-established training programme he has developed and delivers to pharmaceutical executives from across the world, this book will help expand your knowledge in this immense area.
Download or read book The Changing Economics of Medical Technology written by Institute of Medicine and published by National Academies Press. This book was released on 1991-02-01 with total page 225 pages. Available in PDF, EPUB and Kindle. Book excerpt: Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Download or read book Managing Biotechnology written by Francoise Simon and published by John Wiley & Sons. This book was released on 2017-10-16 with total page 322 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive overview of the new business context for biopharma companies, featuring numerous case studies and state-of-the-art marketing models Biotechnology has developed into a key innovation driver especially in the field of human healthcare. But as the biopharma industry continues to grow and expand its reach, development costs are colliding with aging demographics and cost-containment policies of private and public payers. Concurrently, the development and increased affordability of sophisticated digital technologies has fundamentally altered many industries including healthcare. The arrival of new information technology (infotech) companies on the healthcare scene presents both opportunities and challenges for the biopharma business model. To capitalize on new digital technologies from R&D through commercialization requires industry leaders to adopt new business models, develop new digital and data capabilities, and partner with innovators and payers worldwide. Written by two experts, both of whom have had decades of experience in the field, this book provides a comprehensive overview of the new business context and marketing models for biotech companies. Informed by extensive input by senior biotech executives and leading consultancies serving the industry, it analyzes the strategies and key success factors for the financing, development, and commercialization of novel therapeutic products, including strategies for engagement with patients, physicians and healthcare payers. Throughout case studies provide researchers, corporate marketers, senior managers, consultants, financial analysts, and other professionals involved in the biotech sector with insights, ideas, and models. JACQUALYN FOUSE, PhD, RETIRED PRESIDENT AND CHIEF OPERATING OFFICER, CELGENE “Biotech companies have long been innovators, using the latest technologies to enable cutting edge science to help patients with serious diseases. This book is essential to help biotech firms understand how they can–and must–apply the newest technologies including disruptive ones, alongside science, to innovate and bring new value to the healthcare system.” BRUCE DARROW, MD, PhD, CHIEF MEDICAL INFORMATION OFFICER, MOUNT SINAI HEALTH SYSTEM “Simon and Giovannetti have written an essential user’s manual explaining the complicated interplay of the patients who deserve cutting-edge medical care, the biotechnology companies (big and small) creating the breakthroughs, and the healthcare organizations and clinicians who bridge those worlds.” EMMANUEL BLIN, FORMER CHIEF STRATEGY OFFICER AND SENIOR VICE PRESIDENT, BRISTOL-MYERS SQUIBB “If you want to know where biopharma is going, read this book! Our industry is facing unprecedented opportunities driven by major scientific breakthroughs, while transforming itself to address accelerated landscape changes driven by digital revolutions and the emergence of value-based healthcare worldwide. In this ever-changing context, we all need to focus everything we do on the patients. They are why we exist as an industry, and this is ultimately what this insightful essay is really about.” JOHN MARAGANORE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALNYLAM PHARMACEUTICALS “Since the mapping of the human genome was completed nearly 15 years ago, the biotechnology industry has led the rapid translation of raw science to today’s innovative medicines. However, the work does not stop in the lab. Delivering these novel medicines to patients is a complex and multifaceted process, which is elegantly described in this new book.”
Download or read book From Breakthrough to Blockbuster written by Donald L. Drakeman and published by Oxford University Press. This book was released on 2022-02-14 with total page 241 pages. Available in PDF, EPUB and Kindle. Book excerpt: Financial Times Business Top Title March 2022 How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries? Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.
Download or read book Economic Regulation and Its Reform written by Nancy L. Rose and published by University of Chicago Press. This book was released on 2014-08-29 with total page 619 pages. Available in PDF, EPUB and Kindle. Book excerpt: The past thirty years have witnessed a transformation of government economic intervention in broad segments of industry throughout the world. Many industries historically subject to economic price and entry controls have been largely deregulated, including natural gas, trucking, airlines, and commercial banking. However, recent concerns about market power in restructured electricity markets, airline industry instability amid chronic financial stress, and the challenges created by the repeal of the Glass-Steagall Act, which allowed commercial banks to participate in investment banking, have led to calls for renewed market intervention. Economic Regulation and Its Reform collects research by a group of distinguished scholars who explore these and other issues surrounding government economic intervention. Determining the consequences of such intervention requires a careful assessment of the costs and benefits of imperfect regulation. Moreover, government interventions may take a variety of forms, from relatively nonintrusive performance-based regulations to more aggressive antitrust and competition policies and barriers to entry. This volume introduces the key issues surrounding economic regulation, provides an assessment of the economic effects of regulatory reforms over the past three decades, and examines how these insights bear on some of today’s most significant concerns in regulatory policy.
Download or read book Biotechnology and Competitive Advantage written by Jacqueline Senker and published by Edward Elgar Publishing. This book was released on 1998 with total page 200 pages. Available in PDF, EPUB and Kindle. Book excerpt: An investigation of the development of biotechnology in Europe and the United States. It examines why Europe has fallen behind in applying biotechnology, when its scientific capabilities are largely comparable to those in the US. The book also looks at the theory of the growth of new technology.
Download or read book Biotech Industry written by Bryan Bergeron and published by John Wiley & Sons. This book was released on 2004-04-12 with total page 384 pages. Available in PDF, EPUB and Kindle. Book excerpt: "The biotech industry is a complex, rapidly evolving, and critical industry. The industry holds great commercial and societal promise, but it is also filled with hype, confusion, and risks. Bergeron and Chan do a remarkable job of providing a sweeping insightful, and probing assessment of the current state and likely evolution of this global industry. This book is essential reading for the executive who desires a thorough understanding of this business and its potential."--John P. Glasser, Vice President and Chief Information Offers, Partners Healthcare System, Inc. "Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."--Michael A. Greeley, Managing General Partner, IDG Ventures. An in-depth examination of the growth and financing of the biotechnology industry worldwide Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where it's being applied, and where money and intellectual capital are flowing. Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives Eos and other senior-level managers an understanding of Asia's pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.
Download or read book The New Biotechnology written by Margaret Sharp and published by . This book was released on 1985 with total page 156 pages. Available in PDF, EPUB and Kindle. Book excerpt: Research paper on the trends in biotechnology in Japan, the USA and Western Europe - describes its impacts on human and animal health, food industries, beverage industries, chemical industries, the agricultural sector, waste disposal, etc.; includes the role of the private sector, research and development, government policies, patent situation. Graphs, references, statistical tables.
Download or read book Research and Development of Vaccines and Pharmaceuticals from Biotechnology written by Jens-Peter Gregersen and published by Wiley-Blackwell. This book was released on 1994-09-13 with total page 192 pages. Available in PDF, EPUB and Kindle. Book excerpt: Unique in approach, exhaustive in coverage: this book provides information usually not available to scientists. It explains the basic scientific and technical requirements which apply to the patenting and registration of human or veterinary vaccines and therapeutic biomedicinal products. Pragmatic and practice-oriented, it helps users select and manage successfully the most attractive research and development projects. An impressive number of topics is covered, including: * planning and managing product development * product development phases * requirements for a patentable invention * patent costs * user safety * ecotoxicity The book will rapidly pay for itself by more successful fund applications,increased protection and remuneration of intellectual property, and by faster and more efficient product development.
Download or read book Innovation in Pharmaceutical Biotechnology written by Organisation for Economic Co-operation and Development and published by OECD. This book was released on 2006-04-11 with total page 196 pages. Available in PDF, EPUB and Kindle. Book excerpt: This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries - Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain - and makes recommendations advocating an integrated policy approach.
Download or read book Pharmaceutical Biotechnology written by Oliver Kayser and published by Wiley-Blackwell. This book was released on 2006-03-06 with total page 336 pages. Available in PDF, EPUB and Kindle. Book excerpt: With its focus on industrial pharmaceutical research, written by international experts from the industry, this book fills in a gap in the existing literature. It reflects the combination of such pharmaceutical interests as drug delivery, drug targeting, quality and safety management, drug approval and regulation, patenting issues and biotechnology fundamentals. Thus it provides practitioners in pharmaceutical biotechnology with all the relevant information from the shelf. The first part offers a comprehensive survey and review of the rapidly increasing array of biopharmaceuticals derived from the molecular biological approaches now widely available. This is followed by an extra section devoted to the very critical patenting and drug regulation issues. The whole is rounded off by detailed monographs of biotechnologically developed drugs that are already on the market. With a foreword of by Robert Langer, Kenneth J Germeshausen Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. In 2002, he received the Charles Stark Draper Prize, the highest recognition for an engineer. Professor Langer is member of all three national academies - the Institute of Medicine, the National Academy of Engineering, and the National Academy of Sciences: "The book attempts to provide a balanced view of the biotechnological industry and the number of experts from industry sharing their knowledge and experience with the audience gives the book an outstanding value. All contributors provide with each chapter an up-to-date review on key topics in pharmaceutical biotechnology. This work is not only a valuable tool for the industrial expert but also for all pharmacists and scientists from related areas who wish to work with biotech drugs."
Download or read book Systems Biology in Biotech Pharma written by Ales Prokop and published by Springer. This book was released on 2012-01-26 with total page 127 pages. Available in PDF, EPUB and Kindle. Book excerpt: The US is currently well ahead of the rest of the world in the development and application of SB and its principles especially as they pertain to basic medical research and development. This lead is largely due to its earlier start in the academic arena. However, there is evidence of rapid development in both the UK/EU and Japan, and the gap is narrowing, particularly in the UK. From an industrial point of view, the Pharmaceutical Industry based in the US and UK can capitalize on these opportunities and gain the benefits of this technology. Many educational institutions (particularly their medical divisions) at present are heavily business-oriented, realize that in this particular industrial environment, that every dollar counts.
Download or read book Leading Pharmaceutical Innovation written by Oliver Gassmann and published by Springer Science & Business Media. This book was released on 2013-06-05 with total page 184 pages. Available in PDF, EPUB and Kindle. Book excerpt: Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche.
